Lacosamid Puren

Lacosamide, the active ingredient in Lacosamid Puren, is a sodium channel blocker presented as an intravenous solution for intravenous use. It is used as adjunctive therapy for partial‑onset seizures in epilepsy.

GNH USA supplies Lacosamid Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is indicated for seizure disorders that involve abnormal neuronal excitability.

Partial‑onset seizures (focal seizures): Used as adjunctive therapy to reduce seizure frequency in patients with epilepsy. Adjunctive therapy in refractory epilepsy: Provides additional seizure control when other antiepileptics are insufficient. Focal onset seizures in adults: Enhances seizure management as part of a combined antiepileptic regimen.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue - Diplopia (double vision) - Blurred vision

Serious or Rare Side Effects: - Cardiac arrhythmia, including PR‑interval prolongation - Suicidal ideation or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Hypersensitivity reactions (rash, angioedema) - Respiratory depression - Hepatic dysfunction

Lacosamide requires careful monitoring in several clinical situations.

Renal impairment: Adjust dosing and monitor renal function. Hepatic impairment: Monitor liver enzymes and consider dose modification. Cardiac conduction abnormalities: Obtain baseline ECG and monitor PR interval during therapy. Pregnancy: Limited data; weigh potential benefits against risks before use. Concomitant CNS depressants: May increase sedation; observe patient closely. Store at ambient temperature: Keep in original packaging, protect from moisture and light.

Lacosamide may interact with various medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Co‑administration with other sodium‑channel blockers (e.g., carbamazepine) may increase cardiac risk. - Strong CYP3A4 inducers (e.g., rifampin) can markedly reduce lacosamide plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole) may raise lacosamide concentrations and risk toxicity.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs (e.g., valproate) may necessitate dose adjustments. - Alcohol consumption can enhance central nervous system depression. - QT‑prolonging agents require cardiac monitoring for additive effects.